Logo image of ZJYL

JIN MEDICAL INTERNATIONAL LT (ZJYL) Stock Fundamental Analysis

NASDAQ:ZJYL - Nasdaq - KYG5140V1124 - Common Stock - Currency: USD

0.92  +0.03 (+3.37%)

After market: 0.91 -0.01 (-1.09%)

Fundamental Rating

4

ZJYL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. ZJYL has an average financial health and profitability rating. ZJYL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year ZJYL was profitable.
ZJYL had a negative operating cash flow in the past year.
Each year in the past 5 years ZJYL has been profitable.
ZJYL had a positive operating cash flow in 4 of the past 5 years.
ZJYL Yearly Net Income VS EBIT VS OCF VS FCFZJYL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M

1.2 Ratios

ZJYL's Return On Assets of 8.03% is amongst the best of the industry. ZJYL outperforms 89.53% of its industry peers.
ZJYL has a better Return On Equity (12.76%) than 87.96% of its industry peers.
The Return On Invested Capital of ZJYL (7.79%) is better than 86.91% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ZJYL is in line with the industry average of 7.68%.
Industry RankSector Rank
ROA 8.03%
ROE 12.76%
ROIC 7.79%
ROA(3y)9.9%
ROA(5y)10.46%
ROE(3y)14.18%
ROE(5y)16.34%
ROIC(3y)9.49%
ROIC(5y)11.9%
ZJYL Yearly ROA, ROE, ROICZJYL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

The Profit Margin of ZJYL (15.64%) is better than 91.62% of its industry peers.
In the last couple of years the Profit Margin of ZJYL has declined.
The Operating Margin of ZJYL (15.48%) is better than 85.86% of its industry peers.
In the last couple of years the Operating Margin of ZJYL has declined.
ZJYL has a Gross Margin of 40.43%. This is in the lower half of the industry: ZJYL underperforms 68.06% of its industry peers.
ZJYL's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 15.48%
PM (TTM) 15.64%
GM 40.43%
OM growth 3Y6.9%
OM growth 5Y-6.46%
PM growth 3Y7.26%
PM growth 5Y-2.67%
GM growth 3Y9.69%
GM growth 5Y1.86%
ZJYL Yearly Profit, Operating, Gross MarginsZJYL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

5

2. Health

2.1 Basic Checks

ZJYL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, ZJYL has more shares outstanding
Compared to 5 years ago, ZJYL has less shares outstanding
The debt/assets ratio for ZJYL is higher compared to a year ago.
ZJYL Yearly Shares OutstandingZJYL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ZJYL Yearly Total Debt VS Total AssetsZJYL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 7.06 indicates that ZJYL is not in any danger for bankruptcy at the moment.
The Altman-Z score of ZJYL (7.06) is better than 87.43% of its industry peers.
A Debt/Equity ratio of 0.39 indicates that ZJYL is not too dependend on debt financing.
ZJYL has a Debt to Equity ratio (0.39) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Altman-Z 7.06
ROIC/WACC1.02
WACC7.6%
ZJYL Yearly LT Debt VS Equity VS FCFZJYL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

A Current Ratio of 2.50 indicates that ZJYL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.50, ZJYL is in line with its industry, outperforming 47.12% of the companies in the same industry.
ZJYL has a Quick Ratio of 2.19. This indicates that ZJYL is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ZJYL (2.19) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.5
Quick Ratio 2.19
ZJYL Yearly Current Assets VS Current LiabilitesZJYL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

ZJYL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.76%, which is quite good.
The Earnings Per Share has been growing slightly by 3.28% on average over the past years.
The Revenue has grown by 18.57% in the past year. This is quite good.
The Revenue has been growing slightly by 2.90% on average over the past years.
EPS 1Y (TTM)15.76%
EPS 3Y5.52%
EPS 5Y3.28%
EPS Q2Q%66.67%
Revenue 1Y (TTM)18.57%
Revenue growth 3Y4.22%
Revenue growth 5Y2.9%
Sales Q2Q%35.29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZJYL Yearly Revenue VS EstimatesZJYL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 46.00 indicates a quite expensive valuation of ZJYL.
Compared to the rest of the industry, the Price/Earnings ratio of ZJYL indicates a somewhat cheap valuation: ZJYL is cheaper than 68.59% of the companies listed in the same industry.
ZJYL is valuated expensively when we compare the Price/Earnings ratio to 28.33, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 46
Fwd PE N/A
ZJYL Price Earnings VS Forward Price EarningsZJYL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

72.25% of the companies in the same industry are more expensive than ZJYL, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 23.58
ZJYL Per share dataZJYL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15

4.3 Compensation for Growth

ZJYL has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)14.03
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZJYL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JIN MEDICAL INTERNATIONAL LT

NASDAQ:ZJYL (4/22/2025, 8:00:01 PM)

After market: 0.91 -0.01 (-1.09%)

0.92

+0.03 (+3.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.23%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap144.03M
AnalystsN/A
Price TargetN/A
Short Float %0.92%
Short Ratio1.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 46
Fwd PE N/A
P/S 6.13
P/FCF N/A
P/OCF N/A
P/B 5
P/tB 5.21
EV/EBITDA 23.58
EPS(TTM)0.02
EY2.17%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.15
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)14.03
Profitability
Industry RankSector Rank
ROA 8.03%
ROE 12.76%
ROCE 12.7%
ROIC 7.79%
ROICexc 23.55%
ROICexgc 25.79%
OM 15.48%
PM (TTM) 15.64%
GM 40.43%
FCFM N/A
ROA(3y)9.9%
ROA(5y)10.46%
ROE(3y)14.18%
ROE(5y)16.34%
ROIC(3y)9.49%
ROIC(5y)11.9%
ROICexc(3y)22.47%
ROICexc(5y)22.7%
ROICexgc(3y)23.46%
ROICexgc(5y)23.49%
ROCE(3y)12.88%
ROCE(5y)15.84%
ROICexcg growth 3Y-2.39%
ROICexcg growth 5Y-7.19%
ROICexc growth 3Y-4.58%
ROICexc growth 5Y-8.54%
OM growth 3Y6.9%
OM growth 5Y-6.46%
PM growth 3Y7.26%
PM growth 5Y-2.67%
GM growth 3Y9.69%
GM growth 5Y1.86%
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Debt/EBITDA 2.84
Cap/Depr 324.82%
Cap/Sales 4.78%
Interest Coverage 15.2
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.5
Quick Ratio 2.19
Altman-Z 7.06
F-Score3
WACC7.6%
ROIC/WACC1.02
Cap/Depr(3y)128.78%
Cap/Depr(5y)88.37%
Cap/Sales(3y)1.86%
Cap/Sales(5y)1.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.76%
EPS 3Y5.52%
EPS 5Y3.28%
EPS Q2Q%66.67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)18.57%
Revenue growth 3Y4.22%
Revenue growth 5Y2.9%
Sales Q2Q%35.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.9%
EBIT growth 3Y11.4%
EBIT growth 5Y-3.75%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-177.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-138.86%
OCF growth 3YN/A
OCF growth 5YN/A